Enzymatic DNA synthesis is a contemporary technique for producing synthetic DNA, using enzymes (biological catalysts) instead of more conventional chemical techniques (such as phosphoramidite synthesis). Enzymatic DNA synthesis has a number of important advantages as compared to conventional chemical techniques.
Need for precise and effective DNA synthesis techniques has grown in recent years due to developments in synthetic biology and gene editing technologies notably CRISPR-Cas9. Major focus on personalized medicine, where customized DNA sequences are important for creating customized treatments, raises this demand. With growing incidence of chronic illnesses and the search for modern treatment options that includes gene therapy are major factors for market expansion on global scale.
Key Growth Drivers and Opportunities
Rising Incidence of Chronic Diseases: The potential measure of the increasing cases of chronic diseases such as cancer, genetic abnormalities, and cardiovascular ailments, the enzymatic DNA synthesis is commonly known and has grown. Given treatment has ability to produce tailored DNA sequences rapidly and precisely, which is crucial for the development of targeted medications, gene treatments, and molecular diagnostics. As healthcare systems shift towards accurate medicine to better manage chronic illnesses, the need for scalable DNA synthesis technologies is estimated to increase which will drive market expansion on global scale.
Challenges
Major disadvantage includes the enzymatic DNA synthesis that is unable to accurately produce lengthy DNA sequences. There are difficulties regarding the enzymatic procedures that frequently encounter with premature termination, misincorporation of bases, or structural instability of larger chains, in contrast to conventional chemical methods that can consistently manufacture longer strands through stepwise nucleotide addition. This factor limits the adoption of enzymatic DNA synthesis in big gene constructs.
Innovation and Expansion
Ribbon Bio Unveils MiroSynth DNA Molecules
In May 2025, MiroSynth DNA was launched by Ribbon Bio which marks it as first commercial product in enzymatic DNA synthesis that is designed for DNA construction that is complex and high accuracy of product target applications across biopharma, life sciences, and academic research.
Major market including the U.S., EU, UK, and Australia has access to MiroSynth. This launch was termed as “a defining milestone” as the given technology focus on algorithm-driven precision enzymatic assembly and supports both linear and circular DNA formats.
Ansa Biotechnologies Sets New Long-DNA Record
In November 2024, Ansa Clonal DNA was introduced by Ansa Biotechnologies that is able to deliver sequence-perfect clonal DNA up to 5 kilobases. It allows the synthesis of complex DNA with high GC content, hairpins, and repeat regions. Ansa clonal DNA is built on its proprietary sequence-agnostic enzymatic assembly platform and advanced long-read quality control pipeline.
Ansa clonal DNA had its first-pass delivery of challenging constructs according to initial user reports. Given product will make a major impact on research in protein engineering, neuroscience, and therapeutic development.
Molecular Assemblies Launches On-Site FES Partner Program
In May 2024, a new Partnering Program was launched by Molecular Assemblies to license its Fully Enzymatic Synthesis (FES) technology for in-house use. This was one step ahead to decentralized DNA synthesis, giving researchers direct access to long, accurate, and pure DNA production without outsourcing.
This modification aims to provide adequate synthesis capabilities to labs working on synthetic biology, biotherapeutics, and diagnostics. FES technology replicates nature’s writing in DNA using an ecologically safe, water-based enzymatic process.
Inventive Sparks, Expanding Markets
The key companies for enzymatic DNA synthesis are Evonetix, DNA TwoPointO, Inc., GenScript, TELESIS BIO INC., DNA Script, and others. Establishment of strategic alliances and partnerships with biotech firms, educational institutions, and research groups in order to boost innovation and broaden application areas are major focus of these key players propelling the enzymatic DNA synthesis (EDS) market’s expansion.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.